Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

  • Jan Styczynski
  • , Lidia Gil
  • , Gloria Tridello
  • , Per Ljungman
  • , J. Peter Donnelly
  • , Walter Van Der Velden
  • , Hamdy Omar
  • , Rodrigo Martino
  • , Constantijn Halkes
  • , Maura Faraci
  • , Koen Theunissen
  • , Krzysztof Kalwak
  • , Petr Hubacek
  • , Simona Sica
  • , Chiara Nozzoli
  • , Franca Fagioli
  • , Susanne Matthes
  • , Miguel A. Diaz
  • , Maddalena Migliavacca
  • , Adriana Balduzzi
  • Agnieszka Tomaszewska, Rafael De La Camara, Anja Van Biezen, Jennifer Hoek, Simona Iacobelli, Hermann Einsele, Simone Cesaro
  • Nicolaus Copernicus University in Toruń
  • University of Medical Sciences Poznan
  • Policlinico G. B. Rossi
  • Karolinska Institutet
  • Radboud University Nijmegen
  • Hematology, Hospital Santa Creu i Sant Pau
  • Leiden University
  • IRCCS Istituto Giannina Gaslini - Genova
  • KU Leuven
  • Wrocław Medical University
  • Charles University
  • Azienda Ospedaliera Careggi
  • Onco-Ematologia Pediatrica
  • Medical University of Vienna
  • Niño Jesús Children's Hospital
  • University of Milan - Bicocca
  • Institute of Hematology and Blood Transfusion
  • Hospital Universitario de la Princesa
  • University of Rome Tor Vergata
  • University of Würzburg

Risultato della ricerca: Contributo in rivistaArticolo

Abstract

 The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.
Lingua originaleInglese
pagine (da-a)794-802
Numero di pagine9
RivistaClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume57
DOI
Stato di pubblicazionePubblicato - 2013

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

  1. SDG 3 - Salute e benessere
    SDG 3 Salute e benessere

Keywords

  • Epstein-Barr virus
  • hematopoietic stem cell transplantation
  • post-transplant lymphoproliferative disorder
  • prognostic model
  • risk factors

Fingerprint

Entra nei temi di ricerca di 'Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation'. Insieme formano una fingerprint unica.

Cita questo